Also trades as: KIMS.BO (BSE) · $vol 1M
KIMS.NS NSE
Krishna Institute of Medical Sciences Limited
1W: -8.0%
1M: -2.9%
3M: -13.4%
YTD: +13.3%
1Y: +0.7%
3Y: +84.2%
5Y: +194.6%
₹740.00 ($7.69)
-6.40 (-0.86%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$3.1B
-46.1% ▼
5Y CAGR: -2.5%
Capital Expenditures
$14.3B
-41.5% ▼
5Y CAGR: +72.2%
Free Cash Flow
-$11.1B
-161.0% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$187M
+105.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $4.6B | $4.8B | $3.1B | $3.8B | $2.4B |
| Depreciation & Amort. | $727M | $1.3B | $1.5B | $1.8B | $2.8B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$745M | -$693M | $154M | -$769M | -$1.5B |
| Other Non-Cash Items | -$1.3B | -$1.1B | $490M | $970M | -$608M |
| Operating Cash Flow | $3.2B | $4.3B | $5.2B | $5.8B | $3.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.7B | -$5.7B | -$6.5B | -$10.1B | -$14.3B |
| Acquisitions (Net) | -$3.2B | -$1.5B | -$741M | -$1.8B | -$921M |
| Investment Purchases | -$5.8B | -$5.4B | -$2.9B | -$3.8B | -$3.2B |
| Investment Sales | $6.5B | $7.0B | $2.8B | $4.3B | $2.7B |
| Other Investing | $137M | $154M | -$230M | $259M | $16M |
| Investing Cash Flow | -$4.1B | -$5.5B | -$7.5B | -$11.2B | -$15.7B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1.1B | $1.5B | $5.1B | $7.9B | $13.3B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$212M | -$1.3B | -$3.0B | -$2.5B | -$744M |
| Financing Cash Flow | $610M | $196M | $2.2B | $5.4B | $12.5B |
| Net Change in Cash | -$265M | $360M | -$147M | $91M | $187M |
| Cash End of Period | $256M | $616M | $469M | $560M | $747M |
| Free Cash Flow | $1.5B | -$1.4B | -$1.3B | -$4.3B | -$11.1B |